Last reviewed · How we verify

Kineret (ANAKINRA)

Biovitrum Ab · FDA-approved approved Recombinant protein Verified Quality 70/100

Kineret blocks the action of interleukin-1, a protein that promotes inflammation.

Kineret (Anakinra) is a small molecule Interleukin-1 Receptor Antagonist developed by Biovitrum AB, targeting the Interleukin-1 receptor, type I. It was FDA-approved in 2001 for various inflammatory conditions, including rheumatoid arthritis, Still's disease, and familial Mediterranean fever. Kineret works by blocking the action of interleukin-1, a protein that promotes inflammation. The commercial status of Kineret is patented, and it is not yet available as a generic. Key safety considerations include increased risk of infections and neutropenia.

At a glance

Generic nameANAKINRA
SponsorBiovitrum Ab
Drug classInterleukin-1 Receptor Antagonist [EPC]
TargetInterleukin-1 receptor, type I
ModalityRecombinant protein
Therapeutic areaImmunology
PhaseFDA-approved
First approval2001

Mechanism of action

KINERET blocks the biologic activity of IL-1 alpha and beta by competitively inhibiting IL-1 binding to the interleukin-1 type receptor (IL-1RI), which is expressed in wide variety of tissues and organs.IL-1 production is induced in response to inflammatory stimuli and mediates various physiologic responses including inflammatory and immunological responses. IL-1 has broad range of activities including cartilage degradation by its induction of the rapid loss of proteoglycans, as well as stimulation of bone resorption. The levels of the naturally occurring IL-1Ra in synovium and synovial fluid from RA patients are not sufficient to compete with the elevated amount of locally produced IL-1.Spontaneous mutations in the CIAS1/NLRP3 gene have been identified in majority of patients with cryopyrin-associated periodic syndromes such as NOMID. CIAS1/NLRP3 encodes for cryopyrin, component of the inflammasome. The activated inflammasome results in proteolytic maturation

Approved indications

Common side effects

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: